Stocks in news: Vedanta, Kotak Mahindra Bank, Marico, Axis Bank, Trent and Zydus Lifesciences

Indian equity markets staged a recovery on Monday, supported by softer-than-expected US jobs data and a moderation in crude oil prices, providing some relief to investors assessing the near-term interest rate outlook. The Nifty 50 ended the session at 22,555.75, up 133.80 points, or 0.60%.

Technically, the Nifty tested its broken weekly 200-SMA zone at 22,580-22,600 but closed below the band. A sustained move above this zone could extend the recovery towards 22,800, while rejection could keep 22,400 as the immediate support, according to Hariselvan Radhakrishnan, Founder & CEO of HST Wealth.

Against this backdrop, Vedanta, Kotak Mahindra Bank, Marico, Axis Bank, Trent, Zydus Lifesciences and other stocks are likely to remain in focus on Tuesday following key corporate developments and business updates.

Vedanta

Anil Agarwal-led metals and mining major Vedanta Ltd is set to consider its first interim dividend for the financial year 2026-27. The company's Board of Directors is scheduled to meet on Thursday, October 8, 2026, to consider and approve the first interim dividend on equity shares, if any, for FY27. Vedanta has fixed Wednesday, October 14, 2026, as the record date for determining the entitlement of equity shareholders to the proposed dividend, if declared.

Trent

Tata Group's retail arm Trent reported a 23% year-on-year increase in standalone revenue from operations, excluding GST, to Rs 5,788 crore for the quarter ended September 30, 2026, compared with Rs 4,724 crore in the year-ago period, according to its exchange filing. For the first half of FY27, revenue rose 21% year-on-year to Rs 11,454 crore from Rs 9,505 crore in the corresponding period a year earlier.

Marico

Marico has increased its stake in Satiya Nutraceuticals Private Ltd, which owns the ‘The Plant Fix – Plix’ brand, to 84.09% on a fully diluted basis after acquiring an additional 24.09% stake from its founders and certain other shareholders.

In an exchange filing, Marico said it had entered into definitive agreements to acquire a 38.18% stake in Satiya Nutraceuticals on a fully diluted basis, in tranches, from its founders and certain other shareholders, in line with the terms and conditions agreed under the definitive agreements.

Axis Bank

Axis Bank reported a 22.7% year-on-year increase in gross advances to Rs 13.846 lakh crore as of September 30, 2026, compared with Rs 11.284 lakh crore a year earlier, according to the lender's exchange filing. Gross advances increased 8.8% from Rs 12.729 lakh crore at the end of June 2026.

The bank's total deposits rose 20.7% year-on-year to Rs 14.521 lakh crore as of September 30, 2026, from Rs 12.035 lakh crore a year earlier. Deposits increased 5.8% from Rs 13.729 lakh crore at the end of June 2026.

ALSO READ: Indian IT’s Q2 earnings dilemma deepens: More deals but weaker growth and falling pricing power

Narayana Hrudayalaya

Healthcare company Narayana Hrudayalaya said it has entered into an agreement with Mission of Mercy Hospital and Research Centre and The Assemblies of God of North India to operate and manage the Mission of Mercy Hospital & Research Centre at Park Street, Kolkata, on a long-term exclusive basis. The hospital has a capacity of 100 beds and spans approximately 63,240.37 sq ft.

Kotak Mahindra Bank

Kotak Mahindra Bank reported a 24.7% year-on-year increase in net advances to Rs 5,77,094 crore as of September 30, 2026, compared with Rs 4,62,688 crore a year earlier. Net advances increased 12.7% from Rs 5,12,249 crore at the end of June 2026, according to the lender's exchange filing.

Average net advances stood at Rs 5,46,963 crore, up 22.1% year-on-year and 10.5% sequentially.

GAIL

GAIL has appointed Rajeev Kumar as a Non-Executive Director of the company with effect from October 1, 2026.

Juniper Hotels

Juniper Hotels has entered into a binding memorandum of understanding with Imagicaaworld Entertainment to acquire the operating Novotel Imagicaa hotel in Khopoli, Maharashtra, for Rs 248 crore. The 287-room property is spread across approximately 11 acres.

Read more: CAS chaos eases? Jefferies names top stock picks as options volumes recover, IPOs and commodities gain traction

Zydus Lifesciences

Zydus Lifesciences, in partnership with MSN Laboratories, announced the launch of Riociguat Tablets in strengths of 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg in the United States. Zydus and MSN are the first companies to launch a generic version of Adempas (riociguat) in the US market.

Disclosure: This article has been written by Kumar Gaurav, who is not a Sebi-registered Research Analyst or an Investment Adviser. Gaurav and their ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective Sebi-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here